XHKG
6078
Market cap732mUSD
Oct 09, Last price
9.61HKD
1D
1.26%
1Q
-1.94%
IPO
-64.01%
Name
Hygeia Healthcare Holdings Co Ltd
Chart & performance
P/E
30.18
P/S
1.24
EPS
0.27
Div yield, %
—
Shrs. gr., 5y
6.58%
Rev. gr., 5y
23.39%
Revenues
4.01b
-9.84%
Net income
165m
-72.50%
CFO
950m
+34.34%
Dividend
Jun 30, 20230.1636 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hygeia Healthcare Holdings Co., Limited (6078.HK) is a prominent oncology healthcare provider primarily operating across the People's Republic of China. The company owns and manages a network of private, for-profit hospitals specializing in comprehensive cancer care. These facilities offer a broad spectrum of services, including diagnostic procedures such as tumor screening and genetic analysis, advanced therapeutic interventions like radiotherapy, surgery, chemotherapy, immunotherapy, and targeted treatments, alongside crucial supportive care including oncology rehabilitation, nutritional guidance, and hospice services. Beyond direct patient care, Hygeia also provides consulting expertise for radiotherapy centers and licenses its specialized SRT (Stereotactic Radiotherapy) equipment, offering ongoing maintenance and technical support for these systems. The company's operations extend to providing hospital and corporate management services, as well as supply chain solutions. By the end of 2021, Hygeia Healthcare had established a significant presence, operating or managing 12 oncology-focused hospitals spread across 9 cities in 7 provinces throughout mainland China. Established in 2009, the company maintains its headquarters in Shanghai, PRC.
Legal address
C/O Vistra (Cayman) Limited
PO Box 31119, Grand Pavilion
Hibiscus Way
802 West Bay Road
Cayman Bay KY1-1205
KY
PO Box 31119, Grand Pavilion
Hibiscus Way
802 West Bay Road
Cayman Bay KY1-1205
KY
Headquarters
No.228 Meiyuan Road
Room 706
Jingan District
Shanghai, SH 201500
CN
Room 706
Jingan District
Shanghai, SH 201500
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||